Format

Send to

Choose Destination
Cancer Lett. 2020 Jan 31;479:61-70. doi: 10.1016/j.canlet.2020.01.039. [Epub ahead of print]

Monensin, a novel potent MYB inhibitor, suppresses proliferation of acute myeloid leukemia and adenoid cystic carcinoma cells.

Author information

1
Institute for Biochemistry, Westfälische-Wilhelms-Universität, D-48149, Münster, Germany.
2
Sahlgrenska Cancer Center, Department of Pathology, University of Gothenburg, Gothenburg, Sweden.
3
Department of Medicine A, Hematology and Oncology, University Hospital, Westfälische-Wilhelms-Universität, Münster, Germany.
4
Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany.
5
Institute for Biochemistry, Westfälische-Wilhelms-Universität, D-48149, Münster, Germany. Electronic address: klempna@uni-muenster.dge.

Abstract

The master transcriptional regulator MYB is a key oncogenic driver in several human neoplasms, particularly in acute myeloid leukemia (AML) and adenoid cystic carcinoma (ACC). MYB is therefore an attractive target for drug development in MYB-activated malignancies. Here, we employed a MYB-reporter cell line and identified the polyether ionophores monensin, salinomycin, and nigericin as novel inhibitors of MYB activity. As a proof of principle, we show that monensin affects the expression of a significant number of MYB-regulated genes in AML cells and causes down-regulation of MYB expression, loss of cell viability, and induction of differentiation and apoptosis. Furthermore, monensin significantly inhibits proliferation of primary murine AML cells but not of normal hematopoietic progenitors, reflecting a high MYB-dependence of leukemic cells and underscoring the efficacy of monensin in MYB-activated malignancies. Importantly, monensin also suppressed the viability and non-adherent growth of adenoid cystic carcinoma (ACC) cells expressing MYB-NFIB fusion oncoproteins. Our data show that a single compound with significant MYB-inhibitory activity is effective against malignant cells from two distinct MYB-driven human neoplasms. Hence, monensin and related compounds are promising molecular scaffolds for development of novel MYB inhibitors.

KEYWORDS:

ACC; AML; MYB; Monensin; Polyether ionophore; Salinomycin

Conflict of interest statement

Declaration of competing interest The authors declare that they do not have any conflict of interest to disclose.

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center